Relevant bibliographies by topics / Inhibiteur de la PARP

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Inhibiteur de la PARP'

Author: Grafiati
Published: 4 June 2021
Last updated: 16 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Inhibiteur de la PARP.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Inhibiteur de la PARP"

1

Blin, J., and F. Nowak. "Cancer de l’ovaire et inhibiteur de PARP : parcours des patientes en génétique oncologique." Oncologie 19, no. 5-6 (2017): 191–98. http://dx.doi.org/10.1007/s10269-017-2705-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Chabanon, Roman M., and Sophie Postel-Vinay. "Inhibiteurs de PARP." médecine/sciences 35, no. 10 (2019): 728–31. http://dx.doi.org/10.1051/medsci/2019148.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kempe, Sabrina. "Neuer PARP-Inhibitor verfügbar." InFo Hämatologie + Onkologie 23, no. 7-8 (2020): 53. http://dx.doi.org/10.1007/s15004-020-8165-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hofmann-Aßmus, Marion. "Erhaltungstherapie mit PARP-Inhibitor." InFo Onkologie 21, no. 8 (2018): 73. http://dx.doi.org/10.1007/s15004-018-6357-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Dréan, Amy, Christopher J. Lord, and Alan Ashworth. "PARP inhibitor combination therapy." Critical Reviews in Oncology/Hematology 108 (December 2016): 73–85. http://dx.doi.org/10.1016/j.critrevonc.2016.10.010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bollet, M. A., F. Pouzoulet, F. Mégnin, V. Favaudon, and J. Hall. "Inhibiteurs de PARP et radiothérapie." Oncologie 14, no. 4 (2012): 267–70. http://dx.doi.org/10.1007/s10269-012-2115-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lindgren, Anders E. G., Tobias Karlberg, Ann-Gerd Thorsell, et al. "PARP Inhibitor with Selectivity Toward ADP-Ribosyltransferase ARTD3/PARP3." ACS Chemical Biology 8, no. 8 (2013): 1698–703. http://dx.doi.org/10.1021/cb4002014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Juhász, Szilvia, Rebecca Smith, Tamás Schauer, et al. "The chromatin remodeler ALC1 underlies resistance to PARP inhibitor treatment." Science Advances 6, no. 51 (2020): eabb8626. http://dx.doi.org/10.1126/sciadv.abb8626.

Full text
Abstract:
Poly(ADP-ribose) polymerase (PARP) inhibitors are used in the treatment of BRCA-deficient cancers, with treatments currently extending toward other homologous recombination defective tumors. In a genome-wide CRISPR knockout screen with olaparib, we identify ALC1 (Amplified in Liver Cancer 1)—a cancer-relevant poly(ADP-ribose)-regulated chromatin remodeling enzyme—as a key modulator of sensitivity to PARP inhibitor. We found that ALC1 can remove inactive PARP1 indirectly through binding to PARylated chromatin. Consequently, ALC1 deficiency enhances trapping of inhibited PARP1, which then impair
APA, Harvard, Vancouver, ISO, and other styles
9

Romero, Diana. "EMBRACing a new PARP inhibitor?" Nature Reviews Clinical Oncology 15, no. 11 (2018): 655. http://dx.doi.org/10.1038/s41571-018-0090-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Mullard, Asher. "PARP inhibitor pick-me-up." Nature Reviews Drug Discovery 18, no. 11 (2019): 814. http://dx.doi.org/10.1038/d41573-019-00174-w.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Inhibiteur de la PARP"

1

Burckel, Hélène. "Synthèse et évaluation de molécules bifonctionnelles alkylantes de l’ADN et inhibitrices de la PARP pour la radiochimiothérapie concomitante." Thesis, Strasbourg, 2012. http://www.theses.fr/2012STRAJ092.

Full text
Abstract:
Cette étude a consisté en le développement et l’évaluation de nouvelles molécules pour la radiochimiothérapie concomitante. Ce travail a abouti à la conception de nouveaux agents chimiothérapeutiques duaux basés sur la combinaison covalente de deux radiosensibilisateurs: un inhibiteur de la PARP d’une part, et un alkylant de l’ADN (complexe de platine ou témozolomide) d’autre part. Les évaluations biologiques ont permis de mettre en évidence l’intérêt d’une molécule duale inhibiteur de la PARP/platine. Parallèlement à ce projet, le développement d’outils moléculaires pour l’étude d’inhibiteurs
APA, Harvard, Vancouver, ISO, and other styles
2

Castroviejo, Bermejo Marta. "RAD51 as functional biomarker to select tumors for PARP inhibitor treatment." Doctoral thesis, Universitat Autònoma de Barcelona, 2019. http://hdl.handle.net/10803/667273.

Full text
Abstract:
Los inhibidores de la enzima Poly (ADP-ribosa) polimerasa (PARPi) son efectivos en el tratamiento de cánceres que presentan defectos en la reparación del ADN por recombinación homóloga (HRR), incluyendo aquellos con mutaciones en BRCA1 y BRCA2 (BRCA1/2). Se han descrito distintos mecanismos de resistencia a PARPi en tumores con mutaciones germinales en BRCA1/2 (gBRCA), y existen otros tumores sin mutaciones en BRCA1/2 (no-BRCA) que responden a PARPi. Existe la necesidad de desarrollar un biomarcador robusto para una mejor selección de tumores deficientes en HRR y extender el uso de PARPi
APA, Harvard, Vancouver, ISO, and other styles
3

Michels, Judith. "Les Inhibiteurs de PARP dans le Traitement des Cancers Chimio-Résistants. Etude pré-clinique sur la Dépendance à PARP." Phd thesis, Université Paris Sud - Paris XI, 2013. http://tel.archives-ouvertes.fr/tel-01063796.

Full text
Abstract:
Introduction Le cancer bronchique est un problème de santé publique en étant la première cause de décès par cancer dans le monde. Il reste de mauvais pronostic avec une résistance au Cisplatine qui est inéluctable dans l'histoire naturelle de la maladie. Nous nous sommes intéressés à l'association du CDDP aux inhibiteurs de la Poly(ADP-ribose) polymérase. Les inhibiteurs pharmacologiques de PARP sont source d'optimisme en oncologie clinique en monothérapie pour des tumeurs déficientes pour une voie de réparation de l'ADN et en association aux cytotoxiques classiques.Matériel et méthodes Nous a
APA, Harvard, Vancouver, ISO, and other styles
4

Michels, Judith. "Les inhibiteurs de PARP dans le traitement des cancers chimio-résistants : étude pré-clinique sur la dépendance à PARP." Thesis, Paris 11, 2013. http://www.theses.fr/2013PA11T049/document.

Full text
Abstract:
Introduction Le cancer bronchique est un problème de santé publique en étant la première cause de décès par cancer dans le monde. Il reste de mauvais pronostic avec une résistance au Cisplatine qui est inéluctable dans l’histoire naturelle de la maladie. Nous nous sommes intéressés à l’association du CDDP aux inhibiteurs de la Poly(ADP-ribose) polymérase. Les inhibiteurs pharmacologiques de PARP sont source d’optimisme en oncologie clinique en monothérapie pour des tumeurs déficientes pour une voie de réparation de l’ADN et en association aux cytotoxiques classiques.Matériel et méthodes Nous a
APA, Harvard, Vancouver, ISO, and other styles
5

Almeida, Gilberto Serrano de. "Pre-clinical imaging evaluation of the PARP inhibitor rucaparib." Thesis, University of Newcastle upon Tyne, 2013. http://hdl.handle.net/10443/2033.

Full text
Abstract:
Poly(ADP-ribose) polymerase 1 (PARP1) is a DNA-binding enzyme involved in DNA repair by the base-excision pathway. The inhibition of PARP1 is being investigated as a cancer treatment. Rucaparib (CO338) is a potent PARP 31 inhibitor currently in Phase II clinical development. In this thesis P in vivo MR Spectroscopy (MRS) and Dynamic Contrast Enhanced (DCE) MRI were used to study acute effects of rucaparib on energy metabolism and tumour vasculature. 1 31 18 18 Ex vivo H and P-MRS, and in vivo [ F]FLT and [ F]FDG-PET, were used to study effects of treatment with rucaparib on tumour metabolism a
APA, Harvard, Vancouver, ISO, and other styles
6

Ferber-Viart, Chantal. "Les apnées du sommeil : effets d'un inhibiteur des endorphines." Lyon 1, 1993. http://www.theses.fr/1993LYO1T273.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Noel, Georges. "Effets d'un inhibiteur de la poly (ADP-ribose) polymérase 1 (PARP-1) sur la réparation des cassures double-brin de l'ADN et la létalité cellulaire radio-induite en phase S." Paris 11, 2007. http://www.theses.fr/2007PA11T082.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ordway, Gregory A., W. D. Gill, J. B. Coleman, Hui Wang-Heaton, and Russell W. Brown. "Anti-Inflammatory PARP Inhibitor Demonstrates Antidepressant Activity in Animal Model of Treatment Resistant Depression." Digital Commons @ East Tennessee State University, 2019. https://dc.etsu.edu/etsu-works/8643.

Full text
Abstract:
Background: Major depressive disorder is associated with elevated levels of DNA oxidation, DNA damage, and gene expression of DNA repair enzymes including poly (ADP-ribose) polymerase-1 (PARP1). Elevated PARP1 activity is directly linked to neuroinflammation and PARP inhibitors are anti-inflammatory and neuroprotective. We previously showed that PARP inhibitors produce antidepressant-like effects equivalent to fluoxetine in rodent models. Here, we examined whether the PARP inhibitor 3-aminobenzamide (3AB) is effective in a rat model of treatment-resistant depression. Methods: Treatment-resis
APA, Harvard, Vancouver, ISO, and other styles
9

Guillot, Clément. "Potentiel des inhibiteurs de poly(ADP-ribose) polymérases seuls ou en combinaison avec la radiothérapie comme nouvelle option thérapeutique pour le carcinome hépatocellulaire." Thesis, Lyon 1, 2013. http://www.theses.fr/2013LYO10281.

Full text
Abstract:
Le carcinome hépatocellulaire est l'un des cancers les plus fréquents et des plus sévères à travers le monde. Le diagnostic est souvent tardif et les traitements curatifs ne peuvent être proposés qu'à un nombre limité de patients. Les technologies modernes ont permis le développement de nouvelles méthodes de radiothérapie qui montrent aujourd'hui de bons résultats. Par ailleurs, bien que des déficiences dans les voies de réparation de l'ADN soient associées à une instabilité génomique et une susceptibilité au cancer, une inhibition de ces voies sensibilise les cellules cancéreuses à la chimiot
APA, Harvard, Vancouver, ISO, and other styles
10

Mouly, Laetitia. "Rôle de la GTPase Rho RND1 dans la réponse cellulaire à la camptothécine, inhibiteur de la topoisomérase I." Thesis, Toulouse 3, 2018. http://www.theses.fr/2018TOU30030/document.

Full text
Abstract:
La famille des GTPases Rho, comprenant 20 membres, contrôle la dynamique du cytosquelette d'actine et différents processus cellulaires comme la migration. En plus de leurs rôles bien établis, certaines GTPases Rho, notamment RhoB et Rac1, ont émergé en tant que gènes de réponse précoce aux dommages à l'ADN. En effet, RhoB est induite en réponse à divers stress génotoxiques, y compris la camptothécine (CPT), les UV et le cisplatine, et protège principalement les cellules de l'apoptose. Le rôle des autres GTPases Rho en réponse précoce aux génotoxiques reste largement méconnu. Dans ce projet, no
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Inhibiteur de la PARP"

1

Curtin, Nicola J., and Ricky A. Sharma, eds. PARP Inhibitors for Cancer Therapy. Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-14151-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Holfeld, Greg, and Janeen Brian. Super Parp-Buster! HarperCollins Publishers Australia, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bently, Peter. Princesses Don't Parp. Simon & Schuster, Limited, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Mason, Paul, Tony De Saulles, and Gemma Hastilow. Farts That Animals Parp. Hachette Children's Group, 2020.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Zhang, Jei. PARP As a Therapeutic Target. Taylor & Francis Group, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Curtin, Nicola J., and Ricky A. Sharma. PARP Inhibitors for Cancer Therapy. Humana, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Szabo, Csaba. Cell Death: The Role of PARP. Taylor & Francis Group, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Szabo, Csaba. Cell Death: The Role of PARP. CRC, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Winkley, Andrew J. Investigation of parp cleavage in hepatocytes. 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Winograd, Manuel. Indicadores Ambientales Parp Latinoamerica Y El Caribe. World Resources Inst, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Inhibiteur de la PARP"

1

Ferraris, Dana. "Overview of PARP Inhibitor Design and Optimization." In Cancer Drug Discovery and Development. Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-14151-0_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Xu, Guotai, Jos Jonkers, and Sven Rottenberg. "PARP Inhibitor Resistance—What Is Beyond BRCA1 or BRCA2 Restoration?" In Cancer Drug Discovery and Development. Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-14151-0_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Patterson, Miranda J., Yvette Drew, and Nicola J. Curtin. "PARP." In Cancer Therapeutic Targets. Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4419-0717-2_53.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Patterson, Miranda J., Yvette Drew, and Nicola J. Curtin. "PARP." In Cancer Therapeutic Targets. Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4614-6613-0_53-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Baldwin, Paige, Shifalika Tangutoori, and Srinivas Sridhar. "Generation of Dose–Response Curves and Improved IC50s for PARP Inhibitor Nanoformulations." In Methods in Molecular Biology. Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-6646-2_20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Mateo, Joaquin, Timothy A. Yap, and Johann S. De Bono. "PARP Inhibitors." In Management of Castration Resistant Prostate Cancer. Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1176-9_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Schwab, Manfred. "PARP Inhibitors." In Encyclopedia of Cancer. Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-27841-9_4395-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Wang, Junhui, Akira Sato, Hiroaki Fujimori, Yoshio Miki, and Mitsuko Masutani. "PARP and Carcinogenesis." In Cancer Drug Discovery and Development. Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-14151-0_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Dearman, Charles, Ricky A. Sharma, and Nicola J. Curtin. "Biomarkers for PARP Inhibitors." In Cancer Drug Discovery and Development. Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-14151-0_24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ibragimova, Ilsiya, and Paul Cairns. "Assays for Hypermethylation of the BRCA1 Gene Promoter in Tumor Cells to Predict Sensitivity to PARP-Inhibitor Therapy." In Methods in Molecular Biology. Humana Press, 2011. http://dx.doi.org/10.1007/978-1-61779-270-0_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Inhibiteur de la PARP"

1

Chen, Mei-Kuang, Weiya Xia, Qiongzhu Dong, et al. "Abstract 5682: Synergism of PARP inhibitor and MET inhibitor in multiple cancer types with intrinsic and acquired PARP inhibitor resistances." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-5682.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dey, Nandini, Jennifer H. Carlson, Yuliang Sun, Lori S. Friedman, Pradip De, and Brian Leyland-Jones. "Abstract A16: DDR-mediated antitumor actions of PARP inhibitor: Can PI3K-mTOR pathway inhibitor be combined with PARP inhibitor in TNBT?" In Abstracts: AACR Special Conference: Targeting the PI3K-mTOR Network in Cancer; September 14-17, 2014; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-8514.pi3k14-a16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Baldwin, Paige, Anders Ohman, Jeremy Thong, Shifalika Tangutoori, Daniela Dinulescu, and Srinivas Sridhar. "Abstract A03: PARP inhibitor nanotherapy for ovarian cancer." In Abstracts: AACR Special Conference: Advances in Ovarian Cancer Research: Exploiting Vulnerabilities; October 17-20, 2015; Orlando, FL. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1557-3265.ovca15-a03.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

D’Andrea, Alan D. "Abstract IA17: PARP inhibitor resistance in prostate cancer." In Abstracts: AACR Special Conference: Prostate Cancer: Advances in Basic, Translational, and Clinical Research; December 2-5, 2017; Orlando, Florida. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.prca2017-ia17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Makvandi, Mehran, Brian P. Lieberman, Kuiying Xu, et al. "Abstract C15: Predicting response to PARP inhibitors through quantitative measurements of PARP activity in live BRCA1 mutated cells with a radio-iodinated PARP inhibitor." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; November 5-9, 2015; Boston, MA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1535-7163.targ-15-c15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lee, Kyung-Hun, Ahrum Min, Hee Kyung Ahn, et al. "Abstract CT234: VASTUS - a phase 1b/2a basket trial of a new PARP inhibitor, IDX-1197, including PARP inhibitor resistant cohort." In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-ct234.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

D'Andrea, Alan D. "Abstract CN05-02: Novel mechanisms of PARP inhibitor resistance." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; October 26-30, 2017; Philadelphia, PA. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1535-7163.targ-17-cn05-02.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

D'Andrea, Alan D. "Abstract SY29-02: Novel mechanisms of PARP inhibitor resistance." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-sy29-02.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ghosh, Rajib, Sanchita Roy, Francoise Dantzer, and Sonia Franco. "Abstract 3850: Understanding PARP inhibitor sensitivity: Analyses of the genetic interactions between specific PARP inhibitor targets and DNA double-strand repair pathways." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-3850.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Gogola, E., J. Jonkers, and S. Rottenberg. "PO-496 Loss of PARG drives PARP inhibitor resistance in BRCA2-deficient mouse mammary tumours." In Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.513.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Inhibiteur de la PARP"

1

Yazinski, Stephanie. Novel Mechanisms of PARP Inhibitor Resistance in BRCA1-Deficient Breast Cancers. Defense Technical Information Center, 2013. http://dx.doi.org/10.21236/ada612869.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Yazinski, Stephanie. Novel Mechanisms of PARP Inhibitor Resistance in BRCA1-Deficient Breast Cancers. Defense Technical Information Center, 2014. http://dx.doi.org/10.21236/ada614186.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Shea, Lonnie D. Identification of a PARP Inhibitor Sensitivity Signature in Breast Cancer Using a Novel Transcription Factor Activity Array. Defense Technical Information Center, 2012. http://dx.doi.org/10.21236/ada559941.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Zhao, Suyue, Tao Fang, Li Yao, Ying Zheng, Ling Zhang, and Kexiang Zhu. The efficacy and adverse effects of PARP inhibitor combined with chemotherapy compared with chemotherapy alone in the treatment of cancer patient：A protocol for systematic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2020. http://dx.doi.org/10.37766/inplasy2020.9.0087.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Cai, Zhaolun, Chunyu Liu, Chen Chang, et al. Comparative safety of PARP inhibitors in cancer: A network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2021. http://dx.doi.org/10.37766/inplasy2021.3.0018.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Dent, Paul, and Yong Tang. PARP Inhibitors Synergize With Loss of Checkpoint Control to Kill Mammary Carcinoma Cells. Defense Technical Information Center, 2011. http://dx.doi.org/10.21236/ada555901.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Konstantinopoulos, Panagiotis. A Gene Expression Profile of BRCAness that Predicts for Responsiveness to Platinum and PARP Inhibitors. Defense Technical Information Center, 2014. http://dx.doi.org/10.21236/ada613331.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Shao, Fengping, Shanyang He, Yanyun Duan, Yunhe Zhao, Yinguang LI, and Lan Jing. A meta-analysis of efficacy of PARP inhibitors versus conventional therapy or placebo in various cancers patients. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2020. http://dx.doi.org/10.37766/inplasy2020.6.0013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Wu, Meng, HongMei Wang, and ZhengXiang Han. Comparison of PARP Inhibitors as Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2021. http://dx.doi.org/10.37766/inplasy2021.6.0033.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

DeSoto, Joseph A. The Treatment of BRCA1/2 Hereditary Breast Cancer and Sporadic Breast Cancer with Poly(ADP-ribose) PARP-1 Inhibitors and Chemotherapy. Defense Technical Information Center, 2008. http://dx.doi.org/10.21236/ada502786.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Inhibiteur de la PARP' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography